研究者詳細 - 座間味　義人

論文 - 座間味　義人

分割表示 340 件中 161 - 180 件目／全件表示 >>

腎とポリファーマシー対策 CKD・AKI患者におけるポリファーマシー

岡田直人, 中馬真幸, 合田光寛, 八木健太, 座間味義人, 石澤啓介

日本腎臓病薬物療法学会誌 9 ( 特別号 ) S80 - S80 2020年11月

感染と腎機能慢性期(寝たきりの人、筋力の落ちている人)への抗菌薬の使用方法正確な腎機能評価に基づいた抗菌薬の投与設計

岡田直人, 中馬真幸, 合田光寛, 八木健太, 座間味義人, 石澤啓介

日本腎臓病薬物療法学会誌 9 ( 特別号 ) S63 - S63 2020年11月

臨床現場の疑問に応える(答える)腎臓病薬物療法研究臨床現場で勤務する薬剤師の視点を生かしたトランスレーショナルリサーチ

中馬真幸, 座間味義人, 合田光寛, 八木健太, 石澤有紀, 濱野裕章, 岡田直人, 近藤正輝, 楊河宏章, 石澤啓介

日本腎臓病薬物療法学会誌 9 ( 特別号 ) S81 - S81 2020年11月

入院栄養管理において薬剤師に期待される業務の多職種アンケート調査

濱野裕章, 三橋知里, 座間味義人, 岡田直人, 武智研志, 中馬真幸, 石田俊介, 坂本久美子, 合田光寛, 八木健太, 桐野靖, 中村敏己, 石澤啓介

日本病院薬剤師会雑誌 56 ( 10 ) 1181 - 1186 2020年10月

シスプラチン誘発性腎障害を予防する既存薬物の同定と検証

濱野裕章, 池田康将, 合田光寛, 福島圭穣, 岸誠司, 武智研志, 中馬真幸, 座間味義人, 堀之内裕也, 藤野裕道, 石澤啓介, 玉置俊晃

臨床薬理 51 ( Suppl. ) S261 - S261 2020年10月

データ駆動型薬理学・臨床薬理学研究有害事象自発報告データベースを活用した抗がん剤副作用に対する予防法の探索

石澤啓介, 合田光寛, 中馬真幸, 八木健太, 石澤有紀, 座間味義人

臨床薬理 51 ( Suppl. ) S140 - S140 2020年10月

腫瘍循環器学(Cardio-Oncology)研究〜基礎-臨床間の双方向性研究を展開するためにビッグデータ解析と基礎研究を融合した新たな研究手法による腫瘍循環器学へのアプローチ

石澤有紀, 座間味義人, 新村貴博, 合田光寛, 八木健太, 中馬真幸, 今西正樹, 石澤啓介

日本癌学会総会記事 79回 S8 - 2 2020年10月

研究者から見た特定臨床研究推進に寄与する因子臨床研究法施行前後のアンケート調査

八木健太, 中馬真幸, 武智研志, 坂口暁, 軒原浩, 加根千賀子, 佐藤康敬, 新村貴博, 合田光寛, 座間味義人, 石澤啓介, 楊河宏章

臨床薬理 51 ( Suppl. ) S270 - S270 2020年10月

多施設・多職種連携による医薬品適正使用ならびに医療費削減の推進大規模医療情報データベースを活用した有害事象軽減のための多施設共同研究

座間味義人, 川尻雄大, 牛尾聡一郎, 武智研志, 新村貴博, 合田光寛, 八木健太, 中馬真幸, 石澤有紀, 楊河宏章, 石澤啓介

臨床薬理 51 ( Suppl. ) S191 - S191 2020年10月

研究者から見た特定臨床研究推進に寄与する因子臨床研究法施行前後のアンケート調査

八木健太, 中馬真幸, 武智研志, 坂口暁, 軒原浩, 加根千賀子, 佐藤康敬, 新村貴博, 合田光寛, 座間味義人, 石澤啓介, 楊河宏章

臨床薬理 51 ( Suppl. ) S270 - S270 2020年10月

多施設・多職種連携による医薬品適正使用ならびに医療費削減の推進大規模医療情報データベースを活用した有害事象軽減のための多施設共同研究

座間味義人, 川尻雄大, 牛尾聡一郎, 武智研志, 新村貴博, 合田光寛, 八木健太, 中馬真幸, 石澤有紀, 楊河宏章, 石澤啓介

臨床薬理 51 ( Suppl. ) S191 - S191 2020年10月

データ駆動型薬理学・臨床薬理学研究有害事象自発報告データベースを活用した抗がん剤副作用に対する予防法の探索

石澤啓介, 合田光寛, 中馬真幸, 八木健太, 石澤有紀, 座間味義人

臨床薬理 51 ( Suppl. ) S140 - S140 2020年10月

臨床薬理共同研究推進体制の構築に向けた事例紹介

座間味義人, 鈴木啓介, 武智研志, 肥田典子

臨床薬理 51 ( Suppl. ) S111 - S111 2020年10月

入院栄養管理において薬剤師に期待される業務の多職種アンケート調査

濱野裕章, 三橋知里, 座間味義人, 岡田直人, 武智研志, 中馬真幸, 石田俊介, 坂本久美子, 合田光寛, 八木健太, 桐野靖, 中村敏己, 石澤啓介

日本病院薬剤師会雑誌 56 ( 10 ) 1181 - 1186 2020年10月

Preventive Effects of Quercetin against the Onset of Atherosclerosis-Related Acute Aortic Syndromes in Mice. 国際誌

Masateru Kondo, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Mayuko Hosooka, Yuu Kagimoto, Naoko Saito, Rie Matsuoka, Yoshito Zamami, Masayuki Chuma, Kenta Yagi, Kenshi Takechi, Koichi Tsuneyama, Keisuke Ishizawa

International journal of molecular sciences 21 ( 19 ) 2020年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

Atherosclerosis-related acute aortic syndromes, such as aortic aneurysms or aortic dissection are life-threatening diseases. Since they develop suddenly and progress rapidly, the establishment of preventive strategies is urgently needed. Quercetin, a flavonoid abundant in various vegetables and fruits, is suggested to reduce the risk of cardiovascular disease. Therefore, in this study, the preventive effect of quercetin was evaluated using a mouse model of aortic aneurysm and dissection. The model was established by administering angiotensin II (Ang II) and β-aminopropionitrile (BAPN), a lysyl oxidase inhibitor, to mice to induce hypertension and degeneration of the elastic lamina, which would eventually result in the onset of an aortic aneurysm. Ang II, BAPN, and a nitric oxide synthase inhibitor was administered to induce aortic dissection via endothelial dysfunction. Quercetin (60 mg/kg/day) was administered 2 weeks before inducing aortic diseases by the end of the experiments (8 weeks in the aneurysm model, 6 weeks in the dissection model). It was found to reduce the incidence of aneurysm (from 72 to 45%), dissection (from 17 to 10%), and rupture (from 33 to 15%) in mice. Elastin degradation was ameliorated in the quercetin-treated mice compared to that in the mice without quercetin treatment (degradation score 2.9 ± 0.3 vs 2.2 ± 0.2). Furthermore, quercetin suppressed the expression of vascular cell adhesion molecule-1, macrophage infiltration, and pro-matrix metalloproteinase-9 activity. Our results suggest that quercetin might prevent the onset of atherosclerosis-related acute aortic syndromes through its anti-inflammatory and endothelial cell-protective effects.

DOI： 10.3390/ijms21197226

PubMed

researchmap

Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. 国際誌

Naoto Okada, Rie Matsuoka, Takumi Sakurada, Mitsuhiro Goda, Masayuki Chuma, Kenta Yagi, Yoshito Zamami, Yasuhiko Nishioka, Keisuke Ishizawa

Scientific reports 10 ( 1 ) 13773 - 13773 2020年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD) is a fatal irAE that is difficult to treat; moreover, its incidence is relatively higher in patients with lung cancer. Therefore, early ICI-ILD detection and intervention are important for patient safety. However, a risk assessment method for ICI-ILD has not been established and the prediction of ICI-ILD occurrence is difficult. The aim of our study was to identify the risk factors associated with ICI-ILD. To this end, we retrospectively analysed 102 patients with lung cancer who first received ICI and completed the treatment between April 2016 and December 2019 at Tokushima University Hospital. Nineteen patients had all grades of ICI-ILD and 10 had grade ≥ 3 ICI-ILD. The 30-day mortality rate of patients with grade ≥ 3 ICI-ILD was the highest among all patients (P < 0.01). The multivariate logistic analysis indicated that the performance status ≥ 2 alone and both performance status ≥ 2 and ≥ 50 pack-year were independent risk factors of ICI-ILD of grade ≥ 3 and all grades, respectively. Overall, our study provides insights to predict ICI-ILD occurrence.

DOI： 10.1038/s41598-020-70743-2

PubMed

researchmap

Successful Vancomycin Dose Adjustment in a Sepsis patient with Bacterial Meningitis Using Cystatin C.

Masayuki Chuma, Masateru Kondo, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Naoto Okada, Akitomo Shibata, Mizuho Asada, Jun Oto, Hiroaki Yanagawa, Keisuke Ishizawa

Acta medica Okayama 74 ( 4 ) 365 - 370 2020年8月

記述言語：英語

Cystatin C-guided vancomycin (VCM) dosing is useful in critically ill patients. Its usefulness in septic patients with bacterial meningitis remains unknown, as there are no published reports. In this study, we sought to clarify its benefit. Cystatin C was used to guide VCM dosing in a septic bacterial meningitis patient with normal kidney function, according to therapeutic drug monitoring (TDM). Using cystatin C, the Bayesian method-based TDM made optimal VCM dosing possible, and decreased the predicted error (4.85 mg/L) compared to serum creatinine (16.83 mg/L). We concluded TDM of VCM using cystatin C can be considered in sepsis patients with bacterial meningitis with normal kidney function.

DOI： 10.18926/AMO/60376

PubMed

researchmap

Deletion of H-ferritin in macrophages alleviates obesity and diabetes induced by high-fat diet in mice. 査読国際誌

Yasumasa Ikeda, Hiroaki Watanabe, Tetsuya Shiuchi, Hirofumi Hamano, Yuya Horinouchi, Masaki Imanishi, Mitsuhiro Goda, Yoshito Zamami, Kenshi Takechi, Yuki Izawa-Ishizawa, Licht Miyamoto, Keisuke Ishizawa, Ken-Ichi Aihara, Koichiro Tsuchiya, Toshiaki Tamaki

Diabetologia 63 ( 8 ) 1588 - 1602 2020年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

AIMS/HYPOTHESIS: Iron accumulation affects obesity and diabetes, both of which are ameliorated by iron reduction. Ferritin, an iron-storage protein, plays a crucial role in iron metabolism. H-ferritin exerts its cytoprotective action by reducing toxicity via its ferroxidase activity. We investigated the role of macrophage H-ferritin in obesity and diabetes. METHODS: Conditional macrophage-specific H-ferritin (Fth, also known as Fth1) knockout (LysM-Cre Fth KO) mice were used and divided into four groups: wild-type (WT) and LysM-Cre Fth KO mice with normal diet (ND), and WT and LysM-Cre Fth KO mice with high-fat diet (HFD). These mice were analysed for characteristics of obesity and diabetes, tissue iron content, inflammation, oxidative stress, insulin sensitivity and metabolic measurements. RAW264.7 macrophage cells were used for in vitro experiments. RESULTS: Iron concentration reduced, and mRNA expression of ferroportin increased, in macrophages from LysM-Cre Fth KO mice. HFD-induced obesity was lower in LysM-Cre Fth KO mice than in WT mice at 12 weeks (body weight: KO 34.6 ± 5.6 g vs WT 40.1 ± 5.2 g). mRNA expression of inflammatory cytokines and infiltrated macrophages and oxidative stress increased in the adipose tissue of HFD-fed WT mice, but was not elevated in HFD-fed LysM-Cre Fth KO mice. However, WT mice fed an HFD had elevated iron concentration in adipose tissue and spleen, which was not observed in LysM-Cre Fth KO mice fed an HFD (adipose tissue [μmol Fe/g protein]: KO 1496 ± 479 vs WT 2316 ± 866; spleen [μmol Fe/g protein]: KO 218 ± 54 vs WT 334 ± 83). Moreover, HFD administration impaired both glucose tolerance and insulin sensitivity in WT mice, which was ameliorated in LysM-Cre Fth KO mice. In addition, energy expenditure, mRNA expression of thermogenic genes, and body temperature were higher in KO mice with HFD than WT mice with HFD. In vitro experiments showed that iron content was reduced, and lipopolysaccharide-induced Tnf-α (also known as Tnf) mRNA upregulation was inhibited in a macrophage cell line transfected with Fth siRNA. CONCLUSIONS/INTERPRETATION: Deletion of macrophage H-ferritin suppresses the inflammatory response by reducing intracellular iron levels, resulting in the prevention of HFD-induced obesity and diabetes. The findings from this study highlight macrophage iron levels as a potential therapeutic target for obesity and diabetes.

DOI： 10.1007/s00125-020-05153-0

PubMed

researchmap

救急認定薬剤師に今後期待すること救急認定薬剤師に対する研究のすすめ共に歩もう! エビデンス創出へ!!

中馬真幸, 武智研志, 座間味義人, 合田光寛, 石田俊介, 濱野裕章, 近藤正輝, 坂東貴司, 石澤啓介, 楊河宏章

日本臨床救急医学会雑誌 23 ( 3 ) 351 - 351 2020年8月

血液凝固因子製剤の在庫適正化に向けた取り組みによる薬剤廃棄額の削減効果

岡田直人, 神農麻里奈, 中村信元, 三木浩和, 渡辺浩良, 合田光寛, 中馬真幸, 武智研志, 座間味義人, 桐野靖, 中村敏己, 寺岡和彦, 安倍正博, 石澤啓介

日本病院薬剤師会雑誌 56 ( 7 ) 803 - 808 2020年7月

　前のページ - 次のページ　

<座間味 義人>

論文 - 座間味 義人

<座間味　義人>

論文 - 座間味　義人